Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease
<b>Background:</b> Fabry cardiomyopathy is characterized by left ventricular hypertrophy, myocardial fibrosis, arrhythmia, and premature death. Treatment with migalastat, an oral pharmacological chaperone, was associated with a stabilization of cardiac biomarkers and a reduction in left...
Main Authors: | Constantin Gatterer, Dietrich Beitzke, Senta Graf, Max Lenz, Gere Sunder-Plassmann, Christopher Mann, Markus Ponleitner, Robert Manka, Daniel Fritschi, Pierre-Alexandre Krayenbuehl, Philipp Kamm, Olivier Dormond, Frédéric Barbey, Pierre Monney, Albina Nowak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/13/5/1213 |
Similar Items
-
Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists
by: Sebastián Jaurretche, et al.
Published: (2022-09-01) -
Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
by: Fernando Perretta, et al.
Published: (2023-02-01) -
Migalastat como monoterapia oral para la enfermedad de Fabry
by: Fernando Javier Perretta, et al.
Published: (2023-01-01) -
Enfermedad de Fabry: un año en tratamiento con migalastat
by: Juan Camilo Vasquez Gomez, et al.
Published: (2022-09-01) -
A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
by: Michał Nowicki, et al.
Published: (2024-01-01)